A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Thioplex Side Effects, and Drug Interactions - Thiotepa (injection)
Thioplex Side Effects, and Drug Interactions - Thiotepa (injection)
SIDE EFFECTS
In addition to its
effect on the blood-forming
elements (see WARNINGS and
PRECAUTIONS sections), thiotepa
may cause other adverse
reactions.
General: Fatigue, weakness. Febrile reaction
and discharge from
a subcutaneous
lesion may occur as the
result of breakdown of tumor
tissue.
Hypersensitivity Reactions: Allergic reactions - rash,
urticaria, laryngeal edema,
asthma, anaphylactic
shock, wheezing.
Local Reactions: Contact dermatitis,
pain at the injection
site.
Gastrointestinal: Nausea, vomiting,
abdominal pain,
anorexia.
Renal: Dysuria, urinary
retention. There have been rare reports of chemical
cystitis or hemorrhagic
cystitis following
intravesical, but not parenteral
administration
of thiotepa.
Respiratory: Prolonged apnea
has been reported when succinylcholine was administered prior to
surgery, following combined
use of thiotepa and
other anticancer agents. It was theorized that this was caused by
decrease of pseudocholinesterase
activity caused by
the anticancer drugs.
Neurologic: Dizziness, headache,
blurred vision.
Skin: Dermatitis, alopecia. Skin depigmentation
has been reported following topical
use.
Special Senses: Conjunctivitis.
Reproductive: Amenorrhea, interference
with spermatogenesis.
DRUG INTERACTIONS
It is not advisable to combine, simultaneously or sequentially,
cancer chemotherapeutic agents or a cancer
chemotherapeutic agent
and a therapeutic modality having the same mechanism
of action. Therefore, thiotepa
combined with other alkylating agents such
as nitrogen mustard
or cyclophosphamide or thiotepa
combined with irradiation
would serve to intensify toxicity rather than to enhance therapeutic
response. If these agents must follow each other, it is important
that recovery from
the first agent, as indicated
by white blood
cell count, be complete
before therapy with
the second agent is instituted.
Other drugs which are known to produce bone-marrow depression
should be avoided.
top
